Sugi Predict

Sugi Predict / Compounds / SCHEMBL10116370

SCHEMBL10116370

SCHEMBL10116370

CC(C)(C)S(=O)(=O)Nc1ccc(C(=O)Nc2ccc(N3CCCCC3=O)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ KDM4E B2RXH2 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ F10 P00742 10/20 0.56
▸ ATM Q13315 1/20 0.53
▸ F2 P00734 1/20 0.52
▸ RAB9A P51151 4/20 0.52
▸ NPC1 O15118 3/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ TP53 P04637 1/20 0.52
▸ GLA P06280 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ GFER P55789 1/20 0.50
▸ GPR55 Q9Y2T6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116396 0.97 MEN1 (0.61) MEN1KMT2AKDM4EMAPTF10
SCHEMBL27592754 0.88 MEN1 (0.61) MEN1KMT2AKDM4EMAPTF10
SCHEMBL10116685 0.85 KDM4E (0.57) MEN1KMT2AKDM4EMAPTF10
SCHEMBL31680540 0.82 RAB9A (0.70) MEN1KMT2AKDM4EMAPTATM
SCHEMBL10116701 0.81 MEN1 (0.61) MEN1KMT2AKDM4EMAPTF10
SCHEMBL10116232 0.81 MAPT (0.54) MEN1KMT2AKDM4EMAPTATM
SCHEMBL13565293 0.80 LMNA (0.49) MEN1KMT2AKDM4EMAPTNPC1
SCHEMBL10116240 0.79 MEN1 (0.55) MEN1KMT2AKDM4EMAPTRAB9A
SCHEMBL13342311 0.79 RAB9A (0.65) MEN1KMT2AKDM4EMAPTF10
SCHEMBL10114504 0.78 MAPT (0.52) MEN1KMT2AKDM4EMAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
EP-2014285-A1 NPYY5 antagonists Shionogi&Co., Ltd. (JP) 2009-01-14 — — EP disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R MEN1 2876/4885KMT2A 2912/4885KDM4E 1668/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MEN1 2932/4885KMT2A 2768/4885KDM4E 1627/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MEN1 2926/4885KMT2A 2953/4885KDM4E 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.